I copied this from the CFFW website. MRSA isn't mentioned and B. cepacia is handled like it should be.http://www.cfww.org/grants/reports/Resport_Dr_Fustik_Macedonia_April2003.pdfDate: April 15, 2003.R E P O R Tfrom Dr. Stojka Fustik about study visit at DanishCystic Fibrosis Centre, Copenhagen, DenmarkThankful to the grant I had obtained from Cystic Fibrosis Worldwide association, I had a wonderfulopportunity to accomplish a study visit to the Danish Cystic Fibrosis Centre- Copenhagen. Upon aninvitation from Professor Christian Koch my study stay in Copenhagen was from March 16, 2003 toApril 13, 2003.The Danish CF Centre is quite large centre with close to 300 followed patients in all age groups. Iwas able to see a great number of them. Regular monthly visits and survey of the patients to the outpatientsclinic including their clinical status, high ad weight, lung functional tests, andmicrobiological control of respiratory secretions, enabled early detection and treatment of lunginfections and early detection of any worsen of patients' condition. Annual assessment of CF patientsinclude: chest X-ray; hematological parameters (hematology, liver and renal parameters, albumin,total immunoglobulin); IgE and IgG antibodies against A. fumigatus; precipitating antibodies againstP. aeruginosa, S. aureus, H. influenzae and other CF bacterial pathogens; CrEDTA clearance inpatients on repeated aminoglycoside treatment; and oral glucose tolerance test (in patients over 10year of age).I got acquainted in detail with approaches to antibiotic therapy of pulmonary infections of CF patientstreated in the centre. Even in asymptomatic patients, whenever pathogens are identified, the patient istreated according to the antibiogram using high-dose 2-week treatment, with combinationchemotherapy in case of S. aureus. Aggressive antipseudomonas treatment for early P. aeruginosacolonization with inhaled colistin and oral ciprofloxacin is instituted in this centre for many years. Inthis way, they succeed to delay or prevent chronic P. aeruginosa infection in great majority (morethen 80%) of treated patients. In view of the important role chronic P. aeruginosa infection played inmorbidity and mortality in CF, these results are great contribution in improvement of survival andquality of life of the patients.In patients with established chronic P. aeruginosa infection, a regime of elective intravenousantipseudomonas treatment every 3 months is employed. That treatment regime was introduced in theCopenhagen centre in 1976 and it was subsequently followed by an improved long-term prognosisand survival of patients with chronic P. aeruginosa infection. The treatment is intensified by addingdaily inhalations of colistin or tobramycin between the course of intravenous antibiotics andsometimes in unstable patients also by giving oral ciprofloxacin. Patients with chronic P. aeruginosainfection are also on continual oral treatment with azitromycin. The analysis of the effect of long-termtreatment with this macrolid (results presented on the last North American Cystic FibrosisConference) showed the improvement of lung function and nutritional status in treated patients.Unfortunately, the number of CF patients chronically colonized with rarer CF pathogens such as A.xylosoxidans, S maltophilia, Mycobacterium abscessus, and P. apista is increased in the centre. Someof these patients showed marked decline in their clinical status. The treatment of these infections isoften difficult due to multiresistent bacteria strains.The other impressive experience I got from my study visit in the Copenhagen CF centre was theimplementation of high hygienic measures and the strict segregation of patients with different type oflung infections. Patients are seen on separate days in the same out-patients clinic, and patients with.B. cepacia are seen only in a special isolation room. Three separate wards with separate nursing staffare used for hospitalization of CF patients according to status with regard to lung infections. Cohortisolation and improved hygienic precautions have resulted in a decrease/elimination of crossinfectionsand a decrease in overall prevalence of chronic P. aeruginosa infection in the CopenhagenCF centre.During my stay in the Copenhagen CF centre I had pleasure to study medical literature (which is veryinsufficient in my country) and I got a lot of written material about different problems concerning CF.I was present at all meetings and conferences of the CF team. I had discussion with physiotherapistabout the physiotherapeutic methods employed in the centre. The only physiotherapeutic techniquerecommended to all patients from the earliest age, after the diagnosis of the disease, is PEP mask. CFpatients also begin to receive dornasa alfa therapy from infant age, based on the experience of thecentre that the earlier patents receive dornasa alfa, the better long-term outcome may be.I had a meeting with the dietitian and we discussed about nutritional assessment and management ofCF patients in order to maintain adequate nutritional status. I had also pleasure to visit a Clinicalmicrobiology department of Professor Niels Hoiby. Professor Hoiby showed me the laboratories andthe techniques used for bacteriological examination of the secretion obtained from the CF patients'respiratory tract. We discussed about the possibilities for improvement the microbiological diagnosisat our clinic and he expressed willingness for further collaboration.At the end, I would like to thank to all CF team at the Copenhagen Rigshospitalet, especially toProfessor Christian Koch, for their hospitality and their efforts to get me introduced with all treatmentand management of CF patients employed in their center. The experience and knowledge I haveobtained from the study visit of the Danish CF centre would be a significant step forward the betterorganization of the CF centre at the Pediatric clinic in Skopje, as well as for improvement of medicaltreatment and overall care of our CF patients. However, CF is high economic cost chronic disease andthe maintaining of therapeutic programme usually requires significant investment from the familiesand public health support system. Therefore, the treatment is limited by finance in many developingcountries. The efforts have to be done to make the newer medications (Dornasa alfa, Toby) andmaybe potentially new therapies available to wider CF population.I would like to express my gratitude to Cystic Fibrosis Worldwide (CFW) association for financialsupport necessary for realization of this for me very beneficial and fruitful study visit to the DanishCystic Fibrosis Centre in Copenhagen.Kind regards,Stojka Fustik, M.D., Ph.DSkopje,MacedoniaApril 16, 2003